BridgeMD
HOPE in Diabetic Kidney Disease (HyperpOlarised PyruvatE in Diabetic Kidney Disease)
EU CTIS ID: 2023-508824-36-00
What this study is testing
We hypothesise that classification of diabetic kidney disease progression is possible with the application of quantitative hyperpolarised [1-13C]pyruvate MRI.
- Therapeutic exploratory (Phase II)
A plain-language read of the study's public EU CTIS listing. The study team confirms the details.
Who can take part
You may be able to join if
- All participants: Aged 18 – 85 years and pre-menopausal women must be confirmed non-pregnant.
- Type 1 Diabetes Mellitus with diabetic kidney disease: eGFR > 15ml/min and eGFR=< 60 ml/min and urine albumin-creatinine ratio > 100 mg/g)
- Type 1 diabetes mellitus without diabetic kidney disease: eGFR > 60 ml/min and no albuminuria (urine albumin-creatinine ratio < 30 mg/g) and No signs of proliferative retinopathy or macular edema.
- Control Subjects must have eGFR>60
You likely can't join if
- Contraindications for MRI: Significant cardiac disease, Obstructive lung disease, pacemaker, neurostimulator, cholera implant, metal foreign bodies, claustrophobia, largest circumference including arms > 160 cm.
- Competing systemic diseases
- Stents or other devices implanted close to the kidneys that may cause imaging artifacts
- Pyruvate Allergy
The study team makes the final eligibility decision.
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18-64 years, 65+ years. The study team makes the final eligibility decision.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from EU CTIS; the study team decides eligibility.